News

The MAA entitled, ‘TESAMORELIN FERRER,’ was filed on the basis of positive results from two Phase 3 clinical trials. If approved, tesamorelin will receive marketing authorization for the

A research conducted by LifeCycle Pharma demonstrated that certain types of intravenous chemotherapy can be modified, utilizing LifeCycle Pharma technologies, to pill-based therapy. Herlev Hospital Oncology Department chief

Irosustat is an orally available irreversible steroid sulfatase (STS) inhibitor. According to futility analysis, the trial will not meet the primary endpoint and the superiority will not be

The modified complaint includes new claims alleging breach of contract, breach of the implied covenant of good faith and fair dealing, tortious interference with contractual relationships, and civil

Viorra is a non-invasive topical treatment to assist women who are suffering from a range of female sexual arousal disorders (FSAD) that cause a lack of vaginal lubricity

Avastin is a prescription-only medicine that is a solution for intravenous infusion. In the trial, the women who received Avastin showed 52% reduction in the risk of their

Before joining Asmacure, Driscoll served as the CEO and director of Javelin Pharmaceuticals, a developer of acute care pain products. Prior to Javelin, Driscoll held senior positions in

Semuloparin is an investigational selectively engineered Ultra-LMWH (low molecular weight heparin) with enriched anti-thrombin binding sites. Semuloparin reduced the risk of this type of blood clots without increasing

The results from the trial suggested that at five years 66% of patients taking Glivec for three years remained free of cancer recurrence (primary endpoint) compared to 48%